MedTrace Logo

Glucophage XR® Observational Study

NCT01336673 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 518

Last updated 2014-06-19

No results posted yet for this study

Summary

This is a non-interventional, prospective study where no visits or additional interventions to the daily practice of the physician will be performed. Glucophage XR® has recently been available in Thailand for the treatment of patients with type 2 diabetes. A prospective observational study will be valuable to provide information on the day-to-day experience of using Glucophage XR® in the management of this patient population. The data may provide an insight into the use of Glucophage XR® in routine clinical practice in Thailand.

Conditions

  • Diabetes Mellitus Type 2
  • GI Side Effect

Sponsors & Collaborators

  • Merck Ltd., Thailand

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Clinical Research Manager · Merck Ltd., Thailand, an affiliate of Merck KGaA, Darmstadt, Germany

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01336673 on ClinicalTrials.gov